• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年患者中氧烯洛尔与甲基多巴作为二线抗高血压药物的比较。

Comparison of oxprenolol vs methyldopa as second-line antihypertensive agents in the elderly.

作者信息

Traub Y M

机构信息

Department of Internal Medicine A, Rebecca Sieff Medical Center, Safed, Israel.

出版信息

Arch Intern Med. 1988 Jan;148(1):77-80.

PMID:3276279
Abstract

Direct within-patient comparisons of the effects of centrally acting sympathetic inhibitors and beta-blockers on blood pressure (BP) of the elderly have not been done. In the present study, 32 elderly hypertensive patients were treated with a diuretic. Methyldopa (500 mg/d) (16 patients, subgroup A) or slow-release oxprenolol (80 mg/d) (subgroup B) was added as a second-step antihypertensive agent for a period of eight weeks, after which the second-step agents were switched, respectively, for another period of eight weeks. In subgroup A the supine BP dropped from 193/99 to 169/93 mm Hg and the standing BP from 183/100 to 163/92 mm Hg, whereas in subgroup B the supine BP fell from 190/103 to 182/97 mm Hg and the standing BP from 187/101 to 172/95 mm Hg. After switching the drugs, the respective BP values were 177/91 and 170/95 mm Hg and 170/90 and 156/89 mm Hg. In the doses given, methyldopa therapy is more effective than oxprenolol therapy in lowering the BP of elderly hypertensive patients.

摘要

尚未对中枢作用交感神经抑制剂和β受体阻滞剂对老年人血压(BP)的影响进行直接的患者内比较。在本研究中,32例老年高血压患者接受了利尿剂治疗。作为第二步抗高血压药物,分别给16例患者(A亚组)加用甲基多巴(500mg/d)或给另一组患者(B亚组)加用缓释氧烯洛尔(80mg/d),为期8周,之后分别更换第二步用药,再持续8周。在A亚组中,仰卧位血压从193/99mmHg降至169/93mmHg,站立位血压从183/100mmHg降至163/92mmHg;而在B亚组中,仰卧位血压从190/103mmHg降至182/97mmHg,站立位血压从187/101mmHg降至172/95mmHg。换药后,各自的血压值分别为177/91和170/95mmHg以及170/90和156/89mmHg。在给定剂量下,甲基多巴治疗在降低老年高血压患者血压方面比氧烯洛尔治疗更有效。

相似文献

1
Comparison of oxprenolol vs methyldopa as second-line antihypertensive agents in the elderly.老年患者中氧烯洛尔与甲基多巴作为二线抗高血压药物的比较。
Arch Intern Med. 1988 Jan;148(1):77-80.
2
Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.尼日利亚一家三级医院高血压药物治疗的趋势变化:对新旧抗高血压药物的疗效、安全性、合理性和药物经济学的真实世界评估
J Hum Hypertens. 2003 Apr;17(4):277-85. doi: 10.1038/sj.jhh.1001538.
3
Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.动态血压与诊室血压用于评估临床试验中抗高血压疗效:来自Val-Syst研究的见解
Clin Ther. 2004 Sep;26(9):1436-45. doi: 10.1016/j.clinthera.2004.09.003.
4
Efficacy of nitrendipine as baseline antihypertensive therapy.尼群地平作为基础降压治疗的疗效。
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1049-52.
5
Factorial antihypertensive study of an extended-release metoprolol and hydrochlorothiazide combination.美托洛尔缓释片与氢氯噻嗪联合使用的析因降压研究
Am J Hypertens. 2006 Dec;19(12):1217-25. doi: 10.1016/j.amjhyper.2006.05.007.
6
[Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].[原发性高血压患者治疗后昼夜血压及影响因素分析]
Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Aug;25(8):710-4.
7
[Arterial hypertension difficult to control in the elderly patient. The significance of the "white coat effect"].老年患者中难以控制的动脉高血压。“白大衣效应”的意义
Rev Port Cardiol. 1999 Oct;18(10):897-906.
8
The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.氨氯地平和依那普利对患有高血压和非糖尿病肾病的成年人肾功能的影响:一项为期3年的随机、多中心、双盲、安慰剂对照研究。
Clin Ther. 2008 Mar;30(3):482-98. doi: 10.1016/j.clinthera.2008.03.006.
9
Pulse pressure monitoring of open antihypertensive therapy.开放抗高血压治疗中的脉压监测。
Am J Hypertens. 2004 Dec;17(12 Pt 1):1088-94. doi: 10.1016/j.amjhyper.2004.06.024.
10
Experience with a slow-release formulation of oxprenolol.
N Z Med J. 1978 Apr 12;87(609):245-6.